Sleep Disorders

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.

The director of the Sleep Disorders Center and vice-chair of the department of neurology at UCLA David Geffen School of Medicine detailed the greatest need in the management of narcolepsy

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

The Director of the Sleep Disorders Center and vice chair of the department of neurology at UCLA David Geffen School of Medicine describes why labeling patients can lead to a misdiagnosis of narcolepsy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

The Director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed how patients and physicians can be proactive in identifying narcolepsy.

As a marker of impending neurodegeneration, urgency surrounds efforts to slow or stop the progression of REM sleep behavior disorder.